Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma;Chimiothérapie intensive avec support hématopoïé tique chez 22 patients ayant un lymphome primitif du système nerveux central ou un lymphome intraoculaire réfractaire ou en rechute: Mise à jour des résultats

Bulletin du Cancer

Volumn 91, Issue 2, 2004, Pages 189-192

  Soussain, Carole ^a   Hoang Xuan, Khê ^b   Levy, Vincent ^c  

^a CHG   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

Intensive chemotherapy with hematopoietic cells rescue; Intraocular lymphoma; Primary central nervous system lymphoma; Treatment

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; METHOTREXATE; THIOTEPA;

ADULT; ARTICLE; BRAIN DISEASE; BRAIN HEMORRHAGE; BRAIN LYMPHOMA; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; COGNITIVE DEFECT; DRUG DOSE REGIMEN; DRUG MEGADOSE; EYE TUMOR; FEMALE; FOLLOW UP; HEMATOPOIESIS; HUMAN; INTRAOCULAR LYMPHOMA; LEUKOENCEPHALOPATHY; MALE; NEUROLOGICAL COMPLICATION; NEUTROPENIA; PROBLEM SOLVING; PROGNOSIS; RELAPSE; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; CYTARABINE; ETOPOSIDE; EYE NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL; LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC; LYMPHOMA, T-CELL; MIDDLE AGED; PROGNOSIS; RECURRENCE; THIOTEPA;

EID: 1842505561     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1996; 1: 338-46.
2. Blay JY, Bouhour D, Carrie C, Bouffet E, Brunat-Mentigny M, Philip T, et al. The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-hodgkin's lymphoma of patients with no known cause of immunosuppression. Blood 1995; 86: 2922-9.
3. Sarazin M, Ameri A, Monjour A, Nibio A, Poisson M, Delattre JY. Primary central nervous system lymphoma: treatment with chemotherapy and radiotherapy Eur J Cancer 1995; 12: 2003-7.
4. Freilich RJ, Delattre JY, Monjour A, DeAngelis LM. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 1996; 46: 435-9.
5. Arellano-Rodrigo E, Lopez-Guillermo A, Bessel EM, Nomdedeu B, Montserrat E. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 2003; 70: 219-24.
6. Philip T, Guglielmi C, Hagenbeek A, Renier S, Van Der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared to salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-5.
7. Khalfallah S, Stamatoullas A, Fruchart C, Proust F, Delangre T, Tilly H. Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation. Bone Marrow Transplant 1996; 18: 1021-3.
8. Soussain C, Merle-Beral H, Reux I, Sutton L, Fardeau C, Gerber S, et al. A single center study of 11 patients with intraocular lymphoma treated with conventional chemotherapy followed by high-dose chemotherapy and autologous bone marrow transplantation in 5 cases. Leuk Lymphoma 1996; 23: 339-45.
9. Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azat N, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001; 19: 742-9.
10. Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D et al. The Societe Française d'Oncologie Pediatrique LMB89 protocol : highly effective multiagent chemotherapy tailored to the tumor burden and effective response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001; 97: 3370-9.
11. Soussain C, Patte C, Ostronoff M, Delmer A, Rigal-Huguet F, Cambier N, et al. Small noncleaved cell lymphoma and leukemia in adults: a retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 1995; 85: 664-74.
12. Balis FM, Poplack DG. Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol 1989; 11: 74-86.
13. Talha MRZ, Rogers HJ, Trounce JR. Distribution and pharmacokinetics of cyclophosphamide in the rat. Br J Cancer 1980; 41: 140-3.
14. Przepiorka D, Nath R, Ippoliti C, Mehra R, Hagemeisrer F, Diener K, et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leuk Lymphoma 1995; 17: 427-33.
15. Abrey LE, Moskowitz CH, Mason WP, Stewart D, Forsyth PA, Caron DM, et al. A phase II study of intensive methotrexate and cytarabine followed by high dose BEAM chemotherapy with autologous stem cell transplantation (ASCT) in patients with newly diagnosed primary central nervous system lymphoma. Proc Am Soc Clin Oncol 2001; 20: 207.
16. Cheng T, Forsyth P, Chaudhry A, Morris D, Glück S, Russel JA, et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003; 31: 679-85.
17. Corn BW, Sue MM, Topham A, Hauck W, Curran WJ. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000? Cancer 1997; 79: 2409-13.